Novel Treatment for Stroke at Delayed Timepoints
The systemic administration of N,N'-di-1 naphthylguanidine HCl (NAGH) and N,N'-di-p-nitrophenylguanidine HCl (NAD) when administered 24 hours after experimental stroke was found to reduce neural damage and more importantly enhance behavioral recovery
thirty days later. This agent has the potential to extend the therapeutic window several-fold over the currently available treatment methods to many stroke patients. Additionally, this agent provides neural protection leading to recovery of functions, such as motor
skills.This technology is for the treatment of stroke and has the ability to enhance behavioral recovery following a stroke unlike any other method or drug that is currently approved for stroke treatment.
US 9,636,311 issued 2017-05-02 [MORE INFO
Type of Offer:
« More Chemistry Patents« More Medical Patents